Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study release_knpvmsllyjbujntq5zj656phom

by Daniel J Guillaume, Nancy D Doolittle, Seymur Gahramanov, Nancy A Hedrick, Johnny B Delashaw, Edward A Neuwelt

Published in Neurosurgery.

2010   Volume 66, Issue 1, p48-58; discussion 58

Abstract

Refractory anaplastic oligodendroglioma and oligoastrocytoma tumors are challenging to treat. This trial primarily evaluated toxicity and estimated the maximum tolerated dose of intra-arterial (IA) melphalan, IA carboplatin, and intravenous (IV) etoposide phosphate in conjunction with blood-brain barrier disruption in these tumors. The secondary measure was efficacy. Thirteen patients with temozolomide-refractory anaplastic oligodendroglioma (11 patients) or oligoastrocytoma (2 patients) underwent blood-brain barrier disruption with carboplatin (IA, 200 mg/m(2)/d), etoposide phosphate (IV, 200 mg/m(2)/d), and melphalan (IA, dose escalation) every 4 weeks, for up to 1 year. Patients underwent melphalan dose escalation (4, 8, 12, 16, and 20 mg/m(2)/d) until the maximum tolerated dose (1 level below that producing grade 4 toxicity) was determined. Toxicity and efficacy were assessed. Two of 4 patients receiving IA melphalan at 8 mg/m(2)/d developed grade 4 thrombocytopenia; thus, the melphalan maximum tolerated dose was 4 mg/m/d. Adverse events included asymptomatic subintimal tear (1 patient) and grade 4 thrombocytopenia (3 patients). Two patients demonstrated complete response, 3 had partial responses, 5 demonstrated stable disease, and 3 progressed. Median overall progression-free survival was 11 months. Patients with complete or partial response demonstrated deletion of chromosomes 1p and 19q. In the 5 patients with stable disease, 2 demonstrated 1p and 19q deletion, and 3 demonstrated 19q deletion only. In patients with anaplastic oligodendroglioma or oligoastrocytoma tumors in whom temozolomide treatment has failed, osmotic blood-brain barrier disruption with IA carboplatin, IV etoposide phosphate, and IA melphalan (4 mg/m(2)/d for 2 days) shows acceptable toxicity and encouraging efficacy, especially in patients demonstrating 1p and/or 19q deletion.
In text/plain format

Archived Files and Locations

application/pdf  1.1 MB
file_u6kigcodmzci3d7o2n77aenyiy
web.archive.org (webarchive)
europepmc.org (repository)
Read Archived PDF
Archived
Type  article-journal
Stage   published
Year   2010
Language   en ?
PubMed  20023537
PMC  PMC2806091
Container Metadata
Not in DOAJ
In Keepers Registery
ISSN-L:  0148-396X
Work Entity
access all versions, variants, and formats of this works (eg, pre-prints)
Catalog Record
Revision: 27e3b1e3-3f9c-4edb-8dbd-828adc5e3cca
API URL: JSON